Aditxt, Inc. Significantly Increases At-The-Market Offering Capacity by \$36.8 Million

Key Highlights for Investors

• ATM Offering Expansion: Aditxt, Inc. (“Aditxt” or the “Company”) has increased the maximum aggregate offering price of its common stock under its At-The-Market (“ATM”) Offering Agreement with H.C. Wainwright & Co. by an additional \$36,800,000, bringing the total potential offering size to up to \$53,388,964.
• Existing Sales: Prior to this increase, the Company had already sold approximately \$21,257,000 of common stock under the ATM agreement.
• Legal Opinion Filed: A legal opinion from Sheppard Mullin Richter & Hampton, LLP, regarding the legality of the newly authorized shares, was filed as Exhibit 5.1 and incorporated into the Company’s filings for regulatory compliance and investor transparency.
• Prospectus Supplement: A prospectus supplement reflecting the increased offering size has been filed, ensuring that the offering is conducted under current SEC regulations.
• Stock Exchange: Aditxt’s common stock is listed on the Nasdaq Stock Market under the trading symbol “ADTX”.
• Corporate Information: The Company is incorporated in Delaware and has its principal executive offices now listed as 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043.

Details of the Transaction

On March 27, 2026, Aditxt, Inc. announced a substantial increase in its ATM equity offering arrangement. The ATM program, originally established with H.C. Wainwright & Co. on October 25, 2024, enables the Company to sell shares of its common stock, with a par value of \$0.001 per share, directly into the market at prevailing prices. The newly authorized expansion adds \$36.8 million of capacity to the offering, raising the ceiling for potential sales under the agreement to \$53,388,964.

This increase does not include the \$21,257,000 in shares that have already been sold as of the reporting date. The Company has filed a prospectus supplement to update investors and comply with SEC requirements. A key component of the filing is the legal opinion from its counsel, Sheppard Mullin Richter & Hampton, LLP, which affirms the legal validity of the additional shares being offered.

This move gives Aditxt significant financial flexibility and could result in substantial dilution for existing shareholders, depending on how much of the ATM program is utilized and at what price the shares are sold. The proceeds from such offerings are typically used for working capital, operations, and general corporate purposes, but investors should monitor subsequent announcements for any specific use of funds.

Potential Impact on Shareholders

• Share Dilution: The expansion of the ATM offering means Aditxt may issue and sell a significant number of additional shares, potentially resulting in dilution for existing shareholders.
• Price Sensitivity: Large-scale ATM issuances can place downward pressure on the stock price, particularly if shares are sold at market prices over an extended period.
• Increased Liquidity: The ability to raise capital quickly can be positive for the Company’s financial position and flexibility, but investors should consider potential impacts on per-share metrics.
• Regulatory Compliance: Filing of the legal opinion and prospectus supplement demonstrates management’s focus on transparency and compliance, which is important for investor confidence.

Other Important Information

• Not an Emerging Growth Company: Aditxt is not classified as an emerging growth company as defined under SEC rules, which may influence certain disclosure obligations and reporting requirements.
• Recent Changes: The Company has changed its name in the past, previously operating as Aditx Therapeutics, Inc. and ADiTx Therapeutics, Inc.
• Contact Details: New principal office at 2569 Wyandotte Street, Suite 101, Mountain View, CA 94043. Investor relations or inquiries can be directed to the Company’s listed phone numbers.

Conclusion

The expansion of Aditxt’s ATM program by \$36.8 million is a significant development that increases the Company’s capital-raising ability but also introduces potential dilution risk for current shareholders. Investors should closely monitor the Company’s future disclosures regarding actual sales under the program and the intended use of proceeds, as these factors could materially impact the share price and overall valuation.

Disclaimer: This article is for informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any securities. Investors should conduct their own due diligence and consult with a financial advisor before making investment decisions. The information presented is based on filings and disclosures made by Aditxt, Inc. as of the dates referenced and may not reflect subsequent developments.

View Aditxt, Inc. Historical chart here